WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that Notices of
Allowance has been issued for patents covering key technological
features of the Company's Quell® Wearable Pain Relief
Technology™ by the European Patent Office, the Japan Patent Office, and
the State Intellectual Property Office of the People's Republic of China.
The allowed patent claims address an essential element in the Company's
proprietary technology that automatically controls nerve stimulation to
optimize pain relief. In particular, the patent covers a novel
calibration procedure that customizes nerve stimulation for each Quell
In addition, the allowed patent claims protect the unique integrated
Quell design that combines a neurostimulator, an electrode array, and an
accelerometer. This technology enables automatic adjustment of nerve
stimulation based on the user's position and movement, with applications
such as optimizing therapy during sleep. The Company expects the three
patents to formally issue by the third quarter of 2017.
"We are pleased to have received these important Notice of Allowances
for the Quell technology in the European Union, Japan and China. These
are the three key expansion markets for the Quell business," said Shai
N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "We are
currently in discussions with strategic partners about licensing or
distributing Quell outside our core North American market. These patent
claim allowances may help advance these discussions towards formal
Quell is designed for millions of people
suffering from chronic pain. The advanced wearable device is lightweight
and can be worn during the day while active, and at night while
sleeping. It has been cleared by the FDA for treatment of chronic pain
without a prescription. In a recent study, 81% of Quell users reported
an improvement in their chronic pain. Quell users can personalize and
manage therapy discreetly via the Quell Relief app. Quell also offers
advanced health tracking relevant to chronic pain sufferers including
pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW
(South by Southwest) Innovation Award for Best Wearable Technology.
Quell is available at select healthcare professionals and retailers.
for more information.
NeuroMetrix is a commercial stage,
innovation driven healthcare company combining bioelectrical and digital
medicine to address chronic health conditions including chronic pain,
sleep disorders, and diabetes. The company's lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain. Quell is
integrated into a digital health platform that helps patients optimize
their therapy and decrease the impact of chronic pain on their quality
of life. The company also markets DPNCheck®, a rapid
point-of-care test for diabetic neuropathy, which is the most common
long-term complication of Type 2 diabetes. The company maintains an
active research effort and has several pipeline programs. The company is
located in Waltham, Massachusetts and was founded as a spinoff from the
Harvard-MIT Division of Health Sciences and Technology in 1996. For more
information, please visit NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170508005868/en/
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
Source: NeuroMetrix, Inc.
News Provided by Acquire Media